Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
LQDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.26 - $16.92
Previous CloseN/A
Volume97.81K
Average Volume (3M)901.40K
Market Cap
$1.29B
Enterprise Value$826.40M
Total Cash (Recent Filing)$83.68M
Total Debt (Recent Filing)$3.50M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 08, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding85,298,540
10 Day Avg. Volume1,073,248
30 Day Avg. Volume901,397
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)92.15
Price to Cash Flow (P/CF)-15.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit56.60
Enterprise Value/Ebitda-7.71
Forecast
1Y Price Target
$27.63Price Target Upside82.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvantagesYutrepia continues to demonstrate strong potential as a differentiated therapy in PAH and PH-ILD, with clinical data reinforcing its advantages over existing inhaled treprostinil treatments.
Market OpportunityYutrepia will launch into a PAH/PH-ILD opportunity that has grown into a ~$2B market, and should continue expanding to $3B-$4B by 2030 as usage in PH-ILD grows.
Product LaunchLiquidia is on track to launch Yutrepia, its inhaled dry-powder formulation of treprostinil, pending the expiration of Tyvaso DPI’s regulatory exclusivity.
Bears Say
Legal ChallengesThe final legal obstacle for Yutrepia is likely the cross-claim UTHR raised in a lawsuit, but there are low odds of success for UTHR on the challenge.
Regulatory HurdlesThe District Court denied Liquidia’s motion for summary judgment regarding the FDA’s decision to grant United Therapeutics’ Tyvaso DPI regulatory exclusivity.
---
Ownership Overview
36.14% Insiders
5.55% Mutual Funds
0.02% Other Institutional Investors
49.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $8.26 and its highest was $16.92 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $1.29B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is May 08, 2025 which is in 45 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Mar 19, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.375 by -$0.075.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is -0.4.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 85,298,540 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.375. Following the earnings report the stock price went up 1.221%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
---
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.63 (82.74% Upside)
$27.63 (82.74% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 19.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 13.3%
Last 30 Days ▼ 13.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.89%
12-Months-Change
Fundamentals
Return on Equity
-209.35%
Trailing 12-Months
Asset Growth
93.61%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
---
LQDA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment. While there were significant strategic advancements and promising clinical trial results, financial challenges and a decrease in revenue were also highlighted.Read More>---
LQDA Stock 12 Month Forecast
Average Price Target
$27.63
▲(82.74% Upside)
Technical Analysis
Best Analysts Covering LQDA
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+43.73%
reiterated a buy rating 5 days ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +43.73% per trade.
---